Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors

HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. , a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for... | February 9, 2022

Related Keywords

China ,United States ,Michael Molyneaux ,Patrick Lu ,Lysine Co ,Sirnaomics Ltd ,Prnewswire Sirnaomics Ltd ,Company Or Sirnaomics ,Executive Director ,Chief Medical Officer ,Histidine Lysine Co Polymer ,Sirnaomics Ltd Stock Exchange ,News ,Information ,Press Release ,Song ,022 ,Sirnaomics ,Reading ,Iopharmaceutical ,Company ,N ,Discovery ,End ,Development ,F ,Unai ,Nnounced ,The ,Start ,Hase , ,Linical ,Rial 2257 Kyg2050p1028 ,